Respiratory Pharmacotherapy Review

Managing asthma, COPD, and other pulmonary conditions effectively requires a nuanced understanding of drug classes, delivery devices, and personalized treatment strategies. Designing, implementing, and monitoring respiratory drug regimens is a critical skill for clinical practice and success on exams like the NAPLEX where respiratory therapeutics is a heavily weighted domain.

Pathophysiology and Pharmacotherapy Goals

Respiratory pharmacotherapy aims to control symptoms, improve lung function, prevent exacerbations, and enhance quality of life. The approach is fundamentally guided by the underlying pathophysiology. Asthma is characterized by chronic airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction. In contrast, Chronic Obstructive Pulmonary Disease (COPD) involves progressive, largely irreversible airflow limitation due to airway inflammation and parenchymal destruction (emphysema). While inflammation is present in both, it is driven by different cellular mechanisms, which directly informs drug selection. The goal in asthma is complete control, while in COPD, therapy focuses on symptom relief and reducing the frequency and severity of exacerbations.

Core Drug Classes: Mechanisms and Roles

Respiratory medications are categorized by their primary mechanism of action. Understanding these is essential for rational therapy.

Bronchodilators are the cornerstone for immediate symptom relief in both asthma and COPD. They work by relaxing airway smooth muscle. The two main subclasses are beta-2 agonists (e.g., albuterol, salmeterol) and anticholinergics (e.g., ipratropium, tiotropium). Short-acting beta-2 agonists (SABAs) are first-line for acute relief, while long-acting beta-2 agonists (LABAs) are used for maintenance and must always be combined with an anti-inflammatory agent in asthma. Anticholinergics are particularly vital in COPD.

Inhaled corticosteroids (ICS) are the most potent and effective anti-inflammatory controllers for persistent asthma. They reduce airway inflammation, hyperresponsiveness, and mucus production. Examples include fluticasone and budesonide. In COPD, ICS are reserved for patients with a history of exacerbations and elevated eosinophils, and are always combined with a long-acting bronchodilator.

Leukotriene modifiers (e.g., montelukast) offer an oral, non-steroidal anti-inflammatory option. They block the action of leukotrienes, which are inflammatory mediators that cause bronchoconstriction and mucus secretion. They are used as alternative or add-on therapy for asthma, especially in cases of allergic or exercise-induced components, but have a minimal role in COPD.

Biologics are targeted monoclonal antibodies (e.g., omalizumab, mepolizumab, dupilumab) reserved for severe, uncontrolled asthma with specific phenotypes (e.g., allergic, eosinophilic). They inhibit specific components of the inflammatory pathway, such as IgE or interleukin-5.

Mucolytics (e.g., acetylcysteine) help thin viscous respiratory secretions, aiding in their clearance. Their use is primarily in COPD with chronic bronchitis and frequent exacerbations, though the evidence for routine use is modest.

Stepwise and Graded Therapy Approaches

Treatment intensity is not static; it is adjusted in a "stepwise" (asthma) or "graded" (COPD) manner based on symptom control and exacerbation history.

For asthma, the stepwise approach begins at the step most appropriate to disease severity. A patient with intermittent asthma may only need a SABA as needed. With persistent symptoms, Step 2 adds a low-dose ICS. Steps 3 through 5 involve escalating the ICS dose, adding a LABA (forming a combination inhaler), and then considering add-ons like leukotriene modifiers or biologics. The goal is to step up to gain control, then step down to the minimum effective therapy.

For COPD, the GOLD strategy assesses symptoms and exacerbation risk. Group A (less symptoms, low risk) starts with a bronchodilator. Group B (more symptoms, low risk) uses one or two long-acting bronchodilators. Groups C and D (high exacerbation risk) initiate therapy with a LABA/LAMA combination, with the addition of an ICS considered for those with further exacerbations or an eosinophilic phenotype.

Inhaler Device Selection and Technique

The most appropriate medication is ineffective if delivery fails. Inhaler device selection is a critical clinical decision based on patient age, dexterity, inspiratory flow, and preference. There are four main types: Metered-Dose Inhalers (MDIs) require coordination and often a spacer; Dry Powder Inhalers (DPIs) are breath-actuated and require a rapid, deep inhalation; Soft Mist Inhalers (SMIs) are propellant-free and deliver a slow-moving mist; and Nebulizers create an aerosol for those unable to use handheld devices.

Proper inhaler technique is non-negotiable. Common errors include not shaking an MDI, failing to exhale fully before inhalation, inhaling too quickly with a DPI, and not holding breath for 5-10 seconds after inhalation. You must assess and re-teach technique at every opportunity. Device selection should be simplified—using the same type of device for all medications, if possible—to improve adherence and reduce errors.

Monitoring Parameters and Exacerbation Management

Pharmacotherapy requires ongoing assessment. Key monitoring parameters include symptom control (using validated questionnaires like the ACT for asthma), lung function (spirometry, especially FEV1), exacerbation frequency, and medication side effects. For ICS, monitor for oral thrush and dysphonia (minimized with spacer use and rinsing) and potential systemic effects with high doses. For LABAs and LABD/LAMA, be alert for tachycardia and tremor.

Exacerbation management is a critical application of pharmacotherapy. For acute asthma, treatment centers on repeated doses of SABAs (often via nebulizer), systemic corticosteroids (oral or IV), and supplemental oxygen. For COPD exacerbations, the cornerstone is intensified bronchodilation (SABA/SAMA), systemic corticosteroids, and antibiotics if signs of infection are present. A crucial post-exacerbation action is reviewing and reinforcing the maintenance regimen and inhaler technique to prevent recurrence.

Common Pitfalls

1. Incorrect Inhaler Technique: Assuming a patient knows how to use their device is a major error. Correction: Perform a "teach-back" demonstration at every visit. Provide written instructions and recommend spacer use with MDIs.
2. Over-reliance on SABA in Asthma: Overuse (e.g., >1 canister/month) indicates poor control and increased mortality risk. Correction: This is a red flag requiring immediate assessment and escalation of controller therapy (e.g., initiating or increasing ICS dose).
3. Inappropriate Use of ICS in COPD: Prescribing ICS monotherapy for COPD or using it in patients without an exacerbation history or eosinophilic phenotype exposes them to unnecessary risk of pneumonia. Correction: Reserve ICS in COPD for specific indications and always combine with a long-acting bronchodilator.
4. Neglecting a Written Action Plan: Patients without a personalized plan for daily management and exacerbation response have worse outcomes. Correction: Co-create a simple, clear action plan that details maintenance therapy, how to adjust therapy for worsening symptoms, and when to seek emergency care.

Summary

• Respiratory pharmacotherapy is anchored in understanding the distinct pathophysiology of asthma (reversible inflammation) and COPD (largely irreversible obstruction).
• Drug selection follows a stepwise (asthma) or graded (COPD) framework, starting with bronchodilators for relief and adding anti-inflammatory controllers like inhaled corticosteroids as disease persistence or risk increases.
• Inhaler device selection and technique are as important as the drug itself; improper use is a leading cause of treatment failure.
• Effective management requires monitoring symptom scores, lung function, and exacerbations, and actively managing side effects.
• Patient education, including a written action plan and regular technique review, is essential for translating pharmacotherapy into optimal clinical outcomes.